IN BRIEF: Oxford Nanopore signs partnership agreement with bioMerieux

Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore ...

Alliance News 17 April, 2023 | 8:33AM
Email Form Facebook Twitter LinkedIn RSS

Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore sequencing products - Enters a partnership with bioMerieux SA, a company in the field of in vitro diagnostics, to improve health outcomes. Says the partnership will explore opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Oxford Nanopore Chief Executive Officer Gordon Sanghera says: "We are pleased to partner with bioMerieux's IVD expertise to add powerful new tools for the fight against infectious disease. By offering rapid and accurate identification of pathogens and associated antimicrobial resistance, at scale, we hope to better equip the specialists for whom speed and access to comprehensive data is key."

Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. Says both firms are jointly exploring selected opportunities to "advance patient care by providing access to nanopore-based clinical research and in vitro diagnostic solutions".

Current stock price: 239.80 pence each, up 1.2% on Monday morning in London

12-month change: down 30%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Oxford Nanopore Technologies PLC 113.70 GBX 0.71 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures